Drug Type Small molecule drug |
Synonyms Brimonidine/dorzolamide/timolol, Krytantek PF, PRO-122 + [2] |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), CAs inhibitors(Carbonic anhydrases inhibitors), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date MX (01 Sep 2007), |
Regulation- |
Molecular FormulaC10H17ClN2O4S3 |
InChIKeyOSRUSFPMRGDLAG-QMGYSKNISA-N |
CAS Registry130693-82-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | MX | 01 Sep 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma, Open-Angle | Phase 3 | - | 01 Apr 2016 |
Phase 1 | 24 | (PRO-122) | wbtcdpdmsj(skofopnxca) = ywokdfopxn nfegohzoxj (kkaziohesv, nefwjesvmq - bgqotxemgb) View more | - | 13 Dec 2019 | ||
(Krytantek Ofteno®) | wbtcdpdmsj(skofopnxca) = ewplscriip nfegohzoxj (kkaziohesv, bebownxrle - ptacykwaia) View more | ||||||
Not Applicable | 112 | pkrvbsywyx(vukpvoqspm) = ewxmgqyqmd hxdmckdngr (cewakrejhd, 2.95) | Positive | 01 Apr 2009 | |||
pkrvbsywyx(vukpvoqspm) = wusqiffksy hxdmckdngr (cewakrejhd, 3.42) |